ClinVar Miner

Submissions for variant NM_001360.2(DHCR7):c.976G>T (p.Val326Leu) (rs80338859)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Integrated Genetics/Laboratory Corporation of America RCV000007187 SCV000697860 pathogenic Smith-Lemli-Opitz syndrome 2017-05-22 criteria provided, single submitter clinical testing Variant summary: The DHCR7 c.976G>T (p.Val326Leu) variant involves the alteration of a conserved nucleotide and 3/4 in silico tools (SNPsandGO not captured due to low reliability index) predict a benign outcome. This variant was found in 5/104104 control chromosomes at a frequency of 0.000048, which does not exceed the estimated maximal expected allele frequency of a pathogenic DHCR7 variant (0.0043301). Multiple publications have cited the variant in homozygous and compound heterozygous affected individuals. Authors have also indicated the variant to be a common mutation (Ciara_2004). In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic.
Invitae RCV000007187 SCV000835626 pathogenic Smith-Lemli-Opitz syndrome 2019-09-27 criteria provided, single submitter clinical testing This sequence change replaces valine with leucine at codon 326 of the DHCR7 protein (p.Val326Leu). The valine residue is highly conserved and there is a small physicochemical difference between valine and leucine. This variant is present in population databases (rs80338859, ExAC 0.02%). This variant has been observed in combination with other pathogenic variants in several individuals affected with Smith Lemli Opitz syndrome (PMID: 9653161, 15521979, 27513191). ClinVar contains an entry for this variant (Variation ID: 6785). Experimental studies have shown that this missense change drastically reduces DHCR7 protein expression (PMID: 9653161). For these reasons, this variant has been classified as Pathogenic.
Fulgent Genetics,Fulgent Genetics RCV000007187 SCV000893241 pathogenic Smith-Lemli-Opitz syndrome 2018-10-31 criteria provided, single submitter clinical testing
Baylor Genetics RCV000007187 SCV001163693 pathogenic Smith-Lemli-Opitz syndrome criteria provided, single submitter clinical testing
Myriad Women's Health, Inc. RCV000007187 SCV001193943 pathogenic Smith-Lemli-Opitz syndrome 2019-12-20 criteria provided, single submitter clinical testing NM_001360.2(DHCR7):c.976G>T(V326L) is classified as pathogenic in the context of Smith-Lemli-Opitz syndrome and is associated with moderate or mild forms of the disease. Sources cited for classification include the following: PMID 15521979. Classification of NM_001360.2(DHCR7):c.976G>T(V326L) is based on the following criteria: This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening.
OMIM RCV000007187 SCV000027383 pathogenic Smith-Lemli-Opitz syndrome 2004-12-01 no assertion criteria provided literature only
GeneReviews RCV000007187 SCV000040856 pathologic Smith-Lemli-Opitz syndrome 2007-10-24 no assertion criteria provided curation Converted during submission to Pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.